Respective roles of factors II, VII, IX, and X in the procoagulant activity of FEIBA.
Activated prothrombin complex concentrates (APCCs) are effective in the therapy of bleeding episodes in hemophilic patients with inhibitors. We investigated the respective roles of factor II, factor VII, factor IX, and factor X in the procoagulant activity of the APCC FEIBA. Factor II, factor VII, factor IX, and factor X were reduced in platelet-poor plasma, and the thrombin potential (TP) was determined using a chromogenic substrate in the absence or presence of FEIBA. Reduction of factor II resulted in a significant decrease of the TP without influencing the lag phase until the onset of thrombin generation. The reduction of factor VII showed no effect on the TP, but resulted in a prolongation of the lag phase. Changes of factor IX or factor X concentrations showed neither an effect on the TP nor on lag phases. Our study demonstrates that thrombin generation in the presence of FEIBA mainly depends on prothrombin.
Gallistl
S
S
Ludwig Boltzmann Research Institute for Pediatric Hemostasis and Thrombosis, University of Graz, Austria. Siegfried.gallistl@kfunigraz.ac.at
Cvirn
G
G
Leschnik
B
B
Muntean
W
W
D001779:Blood Coagulation Factors / Q000494:pharmacology* / Q000502:physiology*; D005164:Factor IX / Q000502:physiology; D005167:Factor VII / Q000502:physiology; D005170:Factor X / Q000502:physiology; D006487:Hemostasis / Q000187:drug effects*; D006801:Humans; D011516:Prothrombin / Q000502:physiology; D013917:Thrombin / Q000096:biosynthesis / Q000187:drug effects; D019851:Thrombophilia
D001779:Blood Coagulation Factors; D005167:Factor VII; D011516:Prothrombin; D005164:Factor IX; D005170:Factor X; C065655:anti-inhibitor coagulant complex; D013917:Thrombin